These effects are mediated by: Improved endothelial function and nitric oxide bioavailability Reduced vascular inflammation and oxidative stress Stabilization of atherosclerotic plaque Enhanced cardiac metabolism and mitochondrial efficiency From a longevity standpoint, microdosing may maintain low-grade GLP-1 receptor activation within vascular tissue, supporting arterial flexibility, autonomic tone, and lipid regulation without the gastrointestinal intolerance often limiting high-dose use
Published meta-analyses show berberine reduces fasting blood glucose by roughly 1015 mg/dL and HbA1c by 0.50.6% in people with type 2 diabetes or metabolic syndrome (Liang et al., 2019
Cancellations, Refunds, and Commitment Terms Plans auto-renew monthly
But research on GLP-1 microdosing in menopausal populations is limited
Rybelsus is currently FDA-approved for use in patients with type 2 diabetes
Increasing the endogenous secretion of GLP-1 The apical surface of L-cells in the intestinal lining plays a critical role in sensing luminal compounds such as carbohydrates, proteins, gut microbiota, bacteria-derived molecules, bile acids, lipids, fatty acids, and polyphenols
